198 related articles for article (PubMed ID: 12696005)
1. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model.
Ponnuraj EM; Springer J; Hayward AR; Wilson H; Simoes EA
J Infect Dis; 2003 Apr; 187(8):1257-63. PubMed ID: 12696005
[TBL] [Abstract][Full Text] [Related]
2. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
Johnson TR; Graham BS
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
[TBL] [Abstract][Full Text] [Related]
3. Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine.
Ponnuraj EM; Hayward AR; Raj A; Wilson H; Simoes EAF
J Gen Virol; 2001 Nov; 82(Pt 11):2663-2674. PubMed ID: 11602778
[TBL] [Abstract][Full Text] [Related]
4. A primate model of respiratory syncytial virus infection.
Babu PG; Selvan A; Christuraj S; David J; John TJ; Simoes EA
Indian J Exp Biol; 1998 Aug; 36(8):758-62. PubMed ID: 9838875
[TBL] [Abstract][Full Text] [Related]
5. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
[TBL] [Abstract][Full Text] [Related]
6. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.
Peebles RS; Sheller JR; Collins RD; Jarzecka K; Mitchell DB; Graham BS
J Infect Dis; 2000 Sep; 182(3):671-7. PubMed ID: 10950758
[TBL] [Abstract][Full Text] [Related]
8. Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus.
Sawada A; Nakayama T
Microbiol Immunol; 2016 Apr; 60(4):234-42. PubMed ID: 26865035
[TBL] [Abstract][Full Text] [Related]
9. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.
Valosky J; Hishiki H; Zaoutis TE; Coffin SE
Clin Diagn Lab Immunol; 2005 Jan; 12(1):171-9. PubMed ID: 15643003
[TBL] [Abstract][Full Text] [Related]
10. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys.
Cheng X; Zhou H; Tang RS; Munoz MG; Jin H
Virology; 2001 Apr; 283(1):59-68. PubMed ID: 11312662
[TBL] [Abstract][Full Text] [Related]
11. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV.
Johnson TR; Varga SM; Braciale TJ; Graham BS
J Virol; 2004 Aug; 78(16):8753-60. PubMed ID: 15280483
[TBL] [Abstract][Full Text] [Related]
12. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.
Cyr SL; Jones T; Stoica-Popescu I; Burt D; Ward BJ
Vaccine; 2007 Apr; 25(16):3228-32. PubMed ID: 17374422
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.
Johnson TR; Teng MN; Collins PL; Graham BS
J Virol; 2004 Jun; 78(11):6024-32. PubMed ID: 15141000
[TBL] [Abstract][Full Text] [Related]
14.
van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
Antonis AF; van der Most RG; Suezer Y; Stockhofe-Zurwieden N; Daus F; Sutter G; Schrijver RS
Vaccine; 2007 Jun; 25(25):4818-27. PubMed ID: 17499893
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge.
de Waal L; Power UF; Yüksel S; van Amerongen G; Nguyen TN; Niesters HG; de Swart RL; Osterhaus AD
Vaccine; 2004 Feb; 22(8):915-22. PubMed ID: 15161068
[TBL] [Abstract][Full Text] [Related]
17. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
Langley JM; Sales V; McGeer A; Guasparini R; Predy G; Meekison W; Li M; Capellan J; Wang E
Vaccine; 2009 Sep; 27(42):5913-9. PubMed ID: 19651171
[TBL] [Abstract][Full Text] [Related]
18. Formalin-inactivated bovine RSV vaccine influences antibody levels in bronchoalveolar lavage fluid and disease outcome in experimentally infected calves.
Kalina WV; Woolums AR; Gershwin LJ
Vaccine; 2005 Aug; 23(37):4625-30. PubMed ID: 15967545
[TBL] [Abstract][Full Text] [Related]
19. The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease.
Shaw CA; Galarneau JR; Bowenkamp KE; Swanson KA; Palmer GA; Palladino G; Markovits JE; Valiante NM; Dormitzer PR; Otten GR
Vaccine; 2013 Jan; 31(2):306-12. PubMed ID: 23153444
[TBL] [Abstract][Full Text] [Related]
20. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon.
Piedra PA; Wyde PR; Castleman WL; Ambrose MW; Jewell AM; Speelman DJ; Hildreth SW
Vaccine; 1993 Nov; 11(14):1415-23. PubMed ID: 7508665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
